Cardinal Health, Inc. vs Tesla, Inc.: Strategic Comparison

This in-depth comparison examines Cardinal Health, Inc. and Tesla, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cardinal Health, Inc. on its own, evaluating Tesla, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cardinal Health, Inc. and Tesla, Inc. is widest.

On the headline numbers, Cardinal Health, Inc. reports annual revenue of $254.2B against $94.8B for Tesla, Inc., while their respective market capitalizations stand at $56.0B and $1.49T. Both Cardinal Health, Inc. and Tesla, Inc. are headquartered in United States, so they compete in a shared home market and regulatory environment.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

Tesla, Inc.: Tesla, Inc. (NASDAQ: TSLA) is a vertically integrated sustainable energy and technology company based in Austin, Texas. Beyond its leading market share in electric vehicles, Tesla develops grid-scale battery storage, operates the global Supercharger network, and builds artificial intelligence through its Full Self-Driving software and Optimus humanoid robotics programs. For FY2025, Tesla reported $94.83 billion in revenue, $3.79 billion in net income, and 1.64 million vehicle deliveries. It had 134,785 employees at the end of 2025.

Cardinal Health, Inc. and Tesla, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cardinal Health, Inc. and Tesla, Inc..

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

Tesla, Inc. business model: Tesla operates a vertically integrated electric vehicle, clean energy generation, and software ecosystem model. The company generates revenue across four primary pillars: First, Automotive Sales and Leasing, selling mass-market electric vehicles (Model Y, Model 3) and premium models (Model S, Model X, Cybertruck) directly to consumers without franchised dealers. Second, Energy Generation and Storage, manufacturing and deploying utility-scale battery systems (Megapack) and residential solar/Powerwall hardware. Third, Automotive Regulatory Credits, selling zero-emission vehicle credits to legacy automakers needing to meet carbon emissions mandates. Fourth, Services and Other, monetizing the global Supercharger fast-charging network, vehicle maintenance, collision parts, merchandise, and recurring software subscriptions including Full Self-Driving (FSD) and premium connectivity.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cardinal Health, Inc. stack up against those of Tesla, Inc..

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

Tesla, Inc. competitive advantage: Tesla's advantage comes from brand strength, direct sales, software updates, charging infrastructure, battery and powertrain know-how, manufacturing scale, data, and energy-storage growth.

Future prospects matter as much as current results. The growth strategies below explain how Cardinal Health, Inc. and Tesla, Inc. each plan to expand from here.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

Tesla, Inc. growth strategy: Tesla's growth plan rests on four bets. First, regain vehicle volume: deliveries fell 8.6% to 1.64 million in 2025, then rebounded to a record 480,126 in Q2 2026, up 25% year over year. Second, autonomy: Tesla runs a paid robotaxi service in several U.S. cities and is building the steering-wheel-free Cybercab, though the Q2 2026 shareholder letter dropped the target of volume production in 2026. Third, energy storage: Megapack and Powerwall deployments generated $3.14 billion of revenue in Q2 2026, and Megapack 3 is in development. Fourth, software and services: FSD (Supervised) subscriptions, Supercharging and service revenue grew 50% to $4.58 billion in Q2 2026. Optimus humanoid robots are a longer-dated option that Tesla funds from its automotive cash flow.

A closer look at the financial trajectory of Cardinal Health, Inc. and Tesla, Inc. rounds out the comparison.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.

Tesla, Inc.: Tesla's revenue peaked at $97.69 billion in 2024 and slipped 2.9% to $94.83 billion in FY2025, while net income fell from $7.09 billion to $3.79 billion as vehicle prices and regulatory-credit income declined. The second quarter of 2026 reversed the top-line trend: revenue rose 26% to a record $28.24 billion, with automotive up 23% to $20.52 billion, services and other up 50% to $4.58 billion, and energy up 13% to $3.14 billion. Profit did not follow. GAAP net income fell 5% to $1.11 billion and adjusted EPS of $0.33 missed estimates because of higher R&D and AI infrastructure spending.